Hypertension, or high blood pressure, is a common health condition that affects millions of people in Europe and around the world. It is a major risk factor for many serious health conditions, including stroke, heart attack, and kidney disease. Hypertension is also a major contributor to the burden of disease in Europe, with an estimated 2 million deaths attributable to hypertension each year. This article will explore the impact of hypertension on European society, focusing on the prevalence, risk factors, and health outcomes associated with the condition.
Hypertension is a major public health issue in Europe, with an estimated 45 million people affected by the condition. Hypertension is more common in older age groups, with the highest prevalence among those aged 65 and over. Hypertension is also more common in men than women, and in those living in lower socioeconomic groups.
The risk factors for hypertension are well-established and include lifestyle factors such as smoking, physical inactivity, and poor diet. Other risk factors include age, family history, and certain medical conditions such as diabetes and kidney disease.
Hypertension is a major risk factor for a range of serious health conditions, including stroke, heart attack, and kidney disease. Hypertension can also lead to an increased risk of cognitive decline, dementia, and depression. Hypertension is also associated with an increased risk of death, with an estimated 2 million deaths attributable to hypertension each year in Europe.
The impact of hypertension on European society is significant, with the condition leading to an increased burden of disease, increased health care costs, and reduced quality of life. Hypertension is also associated with an increased risk of disability, with an estimated 10 million people in Europe living with a disability caused by hypertension.
The prevention and management of hypertension is essential in order to reduce the burden of the condition on European society. Lifestyle modification is the cornerstone of hypertension management, with a focus on smoking cessation, physical activity, and healthy eating. Other management strategies include the use of medications, such as ACE inhibitors, beta-blockers, and diuretics.
Hypertension is a major public health issue in Europe, with an estimated 45 million people affected by the condition. The impact of hypertension on European society is significant, with the condition leading to an increased burden of disease, increased health care costs, and reduced quality of life. The prevention and management of hypertension is essential in order to reduce the burden of the condition on European society. Lifestyle modification is the cornerstone of hypertension management, with a focus on smoking cessation, physical activity, and healthy eating. Other management strategies include the use of medications, such as ACE inhibitors, beta-blockers, and diuretics.
1.
Belgian Algorithm Reshapes Endometrial Cancer Care
2.
ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer
3.
Nuclear missile workers are contracting cancer: They blame the bases
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology
1.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
2.
Consensus Recommendations for Healthy Hematologic Aging
3.
The Role of Alanine Aminotransferase in Liver Health and Disease
4.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation